Clinical trials: SARS-COV 2
COVID, SARS-CoV 2
Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo
- Trial name
- NCT04408014
- Testing
- Serological test, Nasopharyngeal Swab, Oropharyngeal Swab
- Where
- Brazil
- Volunteers
- 18,901 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
COVID-19 Pandemic, Immunogenicity
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant.
- Conditions
- COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
- Trial name
- SH-MO-214 (NCT05383560)
- Testing
- mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, MRNA-1273.222 Vaccine
- Where
- Israel
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Covid19, SARS-CoV Infection
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
- Trial name
- COVID-FIS (NCT04537299)
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
COVID-19, Neuro-Degenerative Disease
Randomised Clinical Trial to Evaluate the Efficacy of an Online Cognitive Rehabilitation Programme (COPERIA-COG) for Patients With Persistent COVID-19
The pandemic caused by SARS-CoV-2 infection has led to the emergence of diffuse and heterogeneous persistent symptoms in addition to the well-known acute symptoms, which have come to be referred to as persistent COVID.
- Conditions
- COVID-19, Neuro-Degenerative Disease, Psychological, SARS CoV 2 Infection
- Trial name
- COPERIA-COG (NCT05629897)
- Testing
- Sessions of cognitive stimulation
- Where
- 2 sites in Spain
- Volunteers
- 88 people
- Sponsor
- Fundacin Biomedica Galicia Sur
Upper Respiratory Infection
BD Veritor™ At-Home and BD Veritor™ Professional
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection…
- Trial name
- NCT05352581
- Testing
- BD Veritor At-Home, BD Veritor Professional
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 1,146 people
- Sponsor
- Becton, Dickinson and Company
Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS)
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.
- Conditions
- Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
- Trial name
- NCT07189936
- Testing
- To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
COVID, COVID-19
A Study of Combination Therapies to Treat COVID-19 Infection
This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.
- Conditions
- COVID, COVID-19, Corona Virus Infection, Coronavirus Infection
- Trial name
- NCT04459702
- Testing
- hydroxychloroquine, Azithromycin, Ritonavir
- Where
- United States
- Sponsor
- ProgenaBiome
SARS-CoV 2, COVID
Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)
The aim of our study to compare the proportion of patients who develop SARS-CoV-2 disease in 3 groups: patients undergoing a abdominal ultrasound examination in a Specialty Center, patients undergoing endoscopic procedure in a…
- Trial name
- DECORE (NCT04401033)
- Testing
- Telephonic medical visit, Gastrointestinal endoscopy, Abdominal ultrasound
- Where
- Spain
- Volunteers
- 450 people
- Sponsor
- Hospital del Rio Hortega
SARS CoV 2 Infection
Recovering From COVID-19
Following the success of pilot data trialling a virtual community-based remote monitoring model, using Bluetooth enabled pulse oximeters, which demonstrated a saving of 300 bed spaces over a three week period,9 a nationwide…
- Trial name
- OVER-COVID (NCT05302960)
- Testing
- Fitbit
- Sponsor
- Imperial College London
SARS-COV 2, Covid19
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19
This is an open-label, two arm interventional exploratory study to evaluate the safety and efficacy of 5-ALA-Phosphate-SFC during the vaccination of subjects against SARS-CoV-2 (COVID-19) virus infection to define the safety and…
- Trial name
- NCT04854876
- Testing
- 5-ALA-Phosphate + SFC (5-ALA+SFC)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
COVID, SARS-CoV 2
COVID19 Clinical Predictors and Outcome
In December 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, Hubei, China, and now spreads across international borders.
- Trial name
- NCT04416347
- Testing
- SARS-CoV2 Infection
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- St George's University Hospitals NHS Foundation Trust
SARS CoV 2 Infection, COVID-19
Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations
The immune response of COVID-19 vaccination was monitored and studied in the context of the previously PICOV study (P2020/424), Nephro- VAC studies (P2020/284 and P2020/312) and Lung-VAC study (P2021/182).
- Trial name
- COVICO (NCT05667597)
- Testing
- Humoral immunity
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Maria Goossens
SARS-CoV 2, Viral Infection
Anti-SARS Cov-2 T Cell Infusions for COVID 19
This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high…
- Conditions
- SARS-CoV 2, Viral Infection, COVID 19
- Trial name
- BATIT (NCT04401410)
- Testing
- Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
SARS-CoV 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
- Trial name
- CSSC-004 (NCT04373460)
- Testing
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Where
- 29 sites in United States
- Volunteers
- 1,225 people
- Sponsor
- Johns Hopkins University
COVID-19, SARS-CoV 2
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
This is an expanded access program providing COVID-19 convalescent plasma to patients hospitalized with severely or life-threateningly ill COVID-19.
- Conditions
- COVID-19, SARS-CoV 2, SARS-CoV Infection
- Trial name
- NCT04420988
- Testing
- COVID-19 Convalescent Plasma
- Where
- 2 sites in United States
- Sponsor
- Rutgers, The State University of New Jersey
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
Covid19, Corona Virus Infection
Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)
Observational and prospective study with one year of follow-up of the cohort of workers of the CSdM, including workers of subcontracted companies working in the Hospital of Mataró (2,300 workers approximately) and with controls…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV 2, COVID
- Trial name
- SERO-MARES (NCT04425759)
- Testing
- Blood sample
- Where
- Spain
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Hospital de Mataró
Severe Acute Respiratory Syndrome Coronavirus 2
Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.
- Trial name
- DMMETCOV19-2 (NCT04625985)
- Testing
- Metformin Glycinate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
SARS-CoV 2, COVID-19
COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children
There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists.
- Trial name
- CiaoCorona (NCT04448717)
- Testing
- COVID-19 Antibody testing
- Where
- Switzerland
- Volunteers
- 4,250 people, healthy volunteers welcome
- Sponsor
- University of Zurich
COVID, SARS-CoV 2
Characteristics of Patients With COVID-19 in Meta State, Colombia
This observational study aims to collect detailed clinical information on confirmed or suspected patients of COVID-19 treated in hospitals from Meta State, Colombia. The objectives are: 1.
- Conditions
- COVID, SARS-CoV 2, SARS Pneumonia, SARS (Disease)
- Trial name
- NCT04456426
- Sponsor
- Hospital Departamental de Villavicencio